SMAD4 and cancer: This is followed by mutational activation of growth pathways, often through mutations in KRAS or PIK3CA. On several occasions, the TGFβ pathway is affected, e.g., by mutations in SMAD4, while TP53 mutations occur broadly in many cancer types.